Tao Xin is a member of Baker McKenzie's North America Steering Committee for Healthcare & Life Sciences, and currently heads our US Food and Drug Law Practice. A former research biochemist, Xin brings a deep understanding of the complex scientific issues that relate to the US FDA's legal and regulatory requirements, enabling him to help clients with all phases of product development, manufacturing, and marketing. As the science and technology continues to evolve, Xin supports our clients to constantly innovate and push the boundaries of what's possible in the world of life science. Xin is a frequent speaker and writer on US FDA legal developments related to emerging technology, and he has been selected to serve on the 2023 Law360 Life Sciences Editorial Advisory Board.

Based in Washington DC, Xin's practice focuses on empowering global scientific innovation through legal compliance. As a seasoned government regulatory counsel, Xin works closely with companies with novel pharmaceutical, medical device, food, and cosmetic applications that require FDA pre-market approval or clearance and FDA Current Good Manufacturing Practices (cGMP) compliance. Xin has extensive experience advising both emerging and established companies on the launching and promoting innovative products such as cell therapy, software as a medical device (SaMD), cell-cultured meat, and AI-empowered digital health devices. He has represented many life science companies during US government investigations and inspections around the world and helped respond to FDA enforcement actions including Form 483 observations, Warning Letters, and Import Alert. Xin also has a strong track record in FDA product recall matters, and with a deep understanding of the intricacies involved in navigating the complex and interrelated legal and scientific issues, Xin can creatively and effectively represent companies in these bet-the-company cases.

Ms. Anne Wang is the Chief Operating Officer for APCO Greater China region. She has over 18 years of rich experience in the healthcare sector to advise multinational corporations on their public affairs and advocacy strategies in the China market.

Ms. Anne Wang oversees the business operation in the Greater China region for APCO, a global advisory and advocacy firm helping leading corporations, foundations and governments navigate a complex world. Throughout the years, she has been dedicated to fuse the best local experience with a global perspective and has built a diverse and experienced consultant team with a unique culture. In the past 10 years, Ms. Anne Wang led the company’s healthcare practice in the Greater China region and has been providing briefing and counselling on China’s macro-economic and healthcare industrial policies to global and China management teams of multinational companies as well as trade and industrial associations.

Before joining APCO, Ms. Anne Wang worked as a senior project officer in the Health Human Resources Development Center of China's National Health Commission, where she was responsible for international cooperation, policy research and capacity building programs through coordination with various partners including foreign embassies, multinational companies, international universities, and research institutions.

Ms. Anne Wang holds a bachelor’s degree in clinical medicine from Tianjin Medical University and completed a master's in psychology program at the University of Essex in U.K.

Zhiyun Yu joined Matrix Partners China in 2014, he is primarily responsible for the firm's investments in the healthcare sector. The projects led by Zhiyun Yu include Peijia (HK:9996), Rongchang Biotechnology (HK:9995), Kemei Diagnostics (SH:688468), Yifang Bio (SH:688382), Santer Therapeutics, Zhenhe Technology, Enhe Biotechnology, Huahui Anjian, and Wanzhong Yixin, among others. Before joining Matrix Partners, Zhiyun Yu worked at Fidelity Asia Ventures, Shenzhen Venture Capital Group, UBS Investment Bank, McKinsey, Yale University, and Columbia University.

Zhang Hong has abundant experience in corporate affairs, especially in the areas of cross-border M&A (including PE and VC) and joint ventures. She focuses on domestic and overseas cross-border M&A and related legal issues including complicated PE and VC investment and financing, the restructuring involved in dismantling or setting up ‘red-chip’ structures, pre-IPO equity financing and employee incentives for various types of corporations, as well as strategic cooperation and joint venture business. She has accumulated extensive experience and unique insight across a wide range of sectors such as TMT, Fintech, healthcare, real estate, financial institutions, High Tech and high-end manufacturing.

Before joining the Firm, Zhang Hong worked in major Chinese and international lawyer firms. She advised numerous Chinese companies in high-profile overseas M&A and assisted multiple prominent international PE firms’ significant M&A transactions and equity investments in the Greater China and Asia region. Zhang Hong is particularly skilful in advising clients on complicated cross-border transactions and providing input of high commercial value. She has also advised large multinational companies on their M&A and restructuring issues in Greater China and Asia, as well as acting as perennial legal counsel for several large Chinese state-owned enterprises (including government control investment companies). Zhang Hong has been selected as a “Next Generation Lawyer” in both China Corporate and M&A and Private Equity/Venture Capital practices by The Legal 500 Asia Pacific 2018 & 2019. She has also been selected as a “Rising Star” in China Corporate and M&A, “Next Generation Partner” in Private Equity in 2020, as well as a “Next Generation Partner” in Corporate/M&A in Legal 500 Asia Pacific 2023 and 2024.